Activity Overview
This educational activity is an archive of the live presentation held on May 30, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward medical, surgical,
and radiation oncologists; advanced practitioners; nurses; pharmacists; and
other health care providers involved in the management of hepatobiliary
cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate clinical evidence on the safety and efficacy of new immunotherapy approaches for the treatment of hepatobiliary cancers across diverse patient populations
- Integrate the latest evidence and expert guidance into personalized treatment plans for patients with hepatocellular and biliary tract cancers
- Apply multidisciplinary best practices to optimize coordination, continuity, and quality of care for patients with hepatobiliary cancers
Ghassan Abou-Alfa, MD, MBA
Professor of Medicine
Weill Cornell Medical College at Cornell University
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Alligator Bioscience, AstraZeneca, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene Therapeutics, Novartis, Servier, Tango Therapeutics, Tempus, Vector Pharma, Yiviva; Grant/Research Funding: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio Therapeutics, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED Therapeutics, Servier, Yiviva
Riad Salem, MD, MBA
Professor of Radiology, Medicine, and Surgery
Vice-Chair, Image-Guided Therapy
Department of Radiology
Northwestern University
Chicago, IL
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Bard, Boston Scientific, Cook, Eisai, Genentech, Siemens, Sirtex, Trisalus
Rachna Shroff, MD, MS, FASCO
Professor, Department of Medicine
John and Valli Duval Endowed Professor in Gastrointestinal
Oncology
Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
University of Arizona Cancer Center
University of Arizona College of Medicine—Tucson
Tucson, AZ
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Elevar Therapeutics, Genentech, ICON Clinical Research LLC
Arndt Vogel, MD, PhD
Professor of Medicine, University of Toronto
Longo Family Chair in Liver Cancer Research
Clinician Scientist
Division of Gastroenterology and Hepatology, Toronto General
Hospital
Medical Oncology, Princess Margaret Cancer Centre
Toronto General Hospital Research Institute
Schwartz Reisman Liver Research Centre
Institute for Medical Science
Toronto, Canada
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, Biologix, Boehringer Ingelheim, Bristol Myers Squibb, Cogent, Eisai, Elevar, Incyte, Ipsen, Janssen, Jazz Pharmaceuticals, Lilly, Medivir, MSD, Roche, Servier, Taiho, Terumo, Tyra, Zymeworks
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.